Compare stocks

Lonza Group AG is a Swiss multinational chemicals and biotechnology company headquartered in Basel, Switzerland. The company operates primarily in the life sciences sector, offering products and services for pharmaceutical and biotechnology companies, including custom development and manufacturing of active pharmaceutical ingredients, cell and gene therapies, and bioscience solutions. Founded in 1897, Lonza has a significant global presence with numerous production and research facilities worldwide. The company's strategic positioning lies in its comprehensive offering that supports pharmaceutical companies from early-stage development through commercialization, leveraging advanced technologies and extensive expertise in biologics.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.